drugset / Trial / NCT07785102

Single Day of Ultra-accelerated TMS With a Single Dose of NRX-101

NCT07785102 ↗

Phase 0 Not yet recruiting 30 enrolled Mclean Hospital
NaSingle-groupOpen-labelTreatment

Summary

In this pilot study, investigators aim to combine D-cycloserine, lurasidone, and single-day repeated intermittent Theta Burst Stimulation (iTBS) to preliminarily assess clinical improvement in an open-label cohort and monitor for adverse events over a 6-week follow-up period.

Timeline

Start
2026-09-01
Primary completion
2026-12-31
Completion
2027-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Cycloserine Small molecule 175 mg —
Subject Lurasidone Small molecule 8.25 mg —